Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking strategy to diabetes management. These innovative medications operate by mimicking the physiological actions of GLP-1, a hormone secreted by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these compounds enhance insulin production and inhi… Read More

Retaglutide and tirzepatide represent innovative category of medications known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormon… Read More